Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III Epsolay® Program for the Treatment of Papulopustular Rosacea

Stock Information for Sol-Gel Technologies Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sol-Gel Technologies Ltd.

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.